Allianz SE Takes $7.81 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Allianz SE bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,060 shares of the medical research company's stock, valued at approximately $7,814,000.

A number of other institutional investors and hedge funds have also modified their holdings of TMO. Howard Capital Management Group LLC lifted its position in Thermo Fisher Scientific by 0.5% in the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock worth $33,759,000 after buying an additional 286 shares in the last quarter. Principal Financial Group Inc. boosted its position in Thermo Fisher Scientific by 22.1% during the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock valued at $771,876,000 after purchasing an additional 225,568 shares during the last quarter. Isthmus Partners LLC acquired a new position in Thermo Fisher Scientific in the 3rd quarter worth about $353,000. Martingale Asset Management L P lifted its holdings in shares of Thermo Fisher Scientific by 654.5% during the 3rd quarter. Martingale Asset Management L P now owns 8,382 shares of the medical research company's stock valued at $5,185,000 after buying an additional 7,271 shares during the last quarter. Finally, Rockefeller Capital Management L.P. grew its stake in shares of Thermo Fisher Scientific by 0.8% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 244,851 shares of the medical research company's stock valued at $151,432,000 after buying an additional 1,966 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Remove Ads

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. The trade was a 1.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Stephen Williamson sold 9,825 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 3.0 %

Shares of TMO stock traded down $15.09 on Tuesday, reaching $482.51. 1,836,301 shares of the stock were exchanged, compared to its average volume of 1,620,452. The stock has a market cap of $182.03 billion, a PE ratio of 29.19, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a one year low of $481.47 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock has a 50 day moving average price of $540.37 and a 200 day moving average price of $551.02.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.36%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio is currently 10.41%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on TMO shares. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target for the company in a research note on Friday, January 10th. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a research note on Friday, January 31st. Raymond James reissued an "outperform" rating and issued a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. UBS Group upped their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a research report on Friday, January 31st. Finally, Bank of America reduced their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a research report on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $653.23.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.